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The objective of this study was to determine elution properties of meropenem and
compare the elutions of meropenem impregnated PMMA beads without sterilization
(PMMA-Cont) to those sterilized with steam (PMMA-Auto) and ethylene oxide gas
(PMMA-EO). Four groups of beads were produced: one group without antibiotic and
three groups of meropenem impregnated beads: PMMA-Cont, PMMA-Auto, and
PMMA-EO. Antibiotic concentrations in eluent samples were determined using a
microbiological assay at different time intervals.
The microbiological assay resulted in no zone of inhibition at all time periods for
the PMMA-Auto samples and the samples of PMMA without antimicrobial. The
meropenem concentration on the eluent remained above 4 mcg/ml for 15 days in the
PMMA-Cont group and until day 18 for PMMA-EO group. The meropenem incorporated
in the PMMA beads elutes effectively and gradually decreases after the 24 hour peak.
Ethylene oxide does not adversely affect meropenem’s elution.
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CHAPTER I
INTRODUCTION

Local antibiotic use for treatment of infections dates back to 1939 with Jensen’s
discovery that instilling sulfonamide crystals, along with surgical debridement,
hemostasis, primary closure, and immobilization, resulted in a reduced infection rate for
open fractures.1 As systemic antibiotics became available the interest in local use of
antibiotics decreased, but the management of chronic osteomyelitis remained a
challenge.1 A decrease in the blood supply and barriers preventing penetration of
antibiotics at the site of infection make treatment difficult. High antibiotic doses required
to reach therapeutic bactericidal concentrations at the infection site may put the patient at
risk of dose-related toxicity.2 In the 1960’s, the treatment with closed wound irrigationsuction was established as a method of delivering high antibiotic concentrations,
decreasing hematoma formation, promoting influx of leukocytes and tissue fluids and
achieving primary closure to prevent contamination.1, 3 Another method used for delivery
of high antibiotic concentrations to the lower extremities was isolation perfusion. The
affected site was debrided; cannulae were inserted into an artery and vein; a tourniquet
was applied proximally; and oxygenated blood containing high concentrations of
antibiotic was pumped through the distal limb.1 The use of wound irrigation-suction and
isolation perfusion decreased because of the complexity of the procedure and the
introduction of new systemic antibiotics which were more potent against the
1

staphylococci and gram-negative bacilli causing orthopedic infections. With the
introduction of prosthetic joint replacement, the local use of antibiotics resurfaced in
Germany, with the goal to prevent devastating complications as a result of infection in
elective surgical procedures.1 In 1970, Buchholz and Engelbrecht reported antibiotic
elution to local tissues when penicillin, erythromycin and gentamicin were incorporated
into the cement used to attach the total hip prostheses.4 In response to the success in
reducing early postoperative arthroplasty infections, Klemm formed gentamicinimpregnated beads and utilized them to temporarily fill the bone defect after debridement
of the infected bone. He reported a 91.4% cure rate in 128 patients treated for chronic
osteomyelitis.1, 5
Local implantation of antibiotic impregnated polymethylmethacrylate (AIPMMA)
for treatment of orthopedic infections, wound infections and prophylaxis in joint
arthroplasty has gained popularity because of the ability to attain high concentrations of
antibiotic at the site while avoiding adverse effects of systemic toxicity.6, 7 Local therapy
allows use of antibiotics that may be cost prohibitive for long-term systemic
administration.8 Antibiotic tissue concentrations in wounds treated locally with AIPMMA
beads can be as much as twenty times the therapeutic levels obtained in serum with
systemic administration. 9 The use of beads provides a filler for the dead space left after
debridement of bone in patients with chronic osteomyelitis or compound fractures and
allows elution of high concentrations of antibiotic in the surgery site. Increased local
antibiotic concentration may improve the spectrum of susceptible organisms.9 A previous
study comparing systemic antibiotic treatment and AIPMMA treatment did not show a
significant difference in success rate. The same study revealed a 100% success rate when
2

AIPMMA was used in combination with systemic antibiotic treatment. Although this
finding was not statistically significant it suggests that a higher success rate could be
achieved with a treatment combination.10 A multicenter study of six infected total knee
and twenty-two total hip arthroplasties by Nelson et al. documented a similar outcome in
patients treated with debridement, conventional systemic antibiotic therapy and a two
stage delayed reconstruction and in patients treated with debridement, gentamicinPMMA bead implantation and two stage delayed reconstruction.11 No study has
compared the efficacy of systemic antibiotics plus AIPMMA with that of either treatment
alone.1, 11

POLYMETHYLMETHACRYLATE CEMENT
Polymethylmethacrylate bone cement is a high-density polymer formed by mixing
a liquid monomer with a powder polymer. PMMA is porous and does not elicit an
immune response making this material suitable for implantation in the body.1,

7

The

PMMA has no antimicrobial properties, but it is a great vehicle for local antibiotic
delivery.7 Prefabrication of AIPMMA beads reduces surgery time, cost, and results in a
more consistent product. The methylmethacrylate monomer is known to have toxic
effects to musculoskeletal tissue and is still present during the first two hours after mixing
the beads.8 Storage of the product will prevent tissue exposure to the methylmethacrylate
during this period of time. Polymerized PMMA may be cytotoxic if particles are
phagocytized resulting in inhibition of DNA synthesis and cell growth. PMMA may also
stimulate tumor growth in rodents and result in bacterial infection, but there is no
evidence that it affects reactivity of IgA, IgG, or IgM and does not alter the body’s
3

response to bacterial chemotactic factors. Even though it does not affect immunity, it
may have negative effects on bacterial inhibiting factors, lymphocyte function, late-acting
components of the complement sequence and polymorphonuclear cell function. Release
of small amounts of monomer into the systemic circulation may occur, but it has not been
associated with any toxic effects.8 The most commonly used commercial PMMA cements
are Palacos® (Merck KGaA, Darmstadt, Germany), used primarily in Europe and
SimplexTM P (Howmedica, Rutherford, N.J.) used in the United States and the United
Kingdom.

Palacos® PMMA cement (Palacos-Refobacin) and beads (Septopal®)

containing gentamicin are manufactured and available commercially in Germany.1
Prefabrication of antibiotic beads and gas sterilization for “off the shelf” availability has
been reported, but no product has been approved for commercial use in the United
States.6 The surgeon has three bead manufacturing options which include commercially
manufactured (Septopal®; Kulzer, Wehrheim, Germany), mold-made or hand-rolled
beads.

Currently, PMMA beads are made intraoperatively by hand, a method that

prolongs surgery time and is both inefficient and inconsistent. Seligson et al. compared
the amount of aminoglycoside eluting from the beads manufactured with the three
different methods and found no statistically significant differences in antibiotic elution.6
The authors concluded that elution rate is independent of the fabrication mode as long as
the bead is similar in size and is composed of the same material. 12 To add an antibiotic to
the PMMA, the antibiotic is mixed with the powder cement polymer before addition of
the liquid methylmethacrylate. The antibiotic used should be a broad-spectrum antibiotic
if empirical treatment is instituted, active against the etiologic pathogen and must be
available as a powder.

Mechanical studies demonstrated that the admixture of
4

gentamicin, oxacillin, and cefazolin powders did not have any effects on the color,
viscosity, set times or compressive and diameter tension strengths of the PMMA.1 The
use of antibiotic solutions is not recommended since they have been shown to reduce the
mixing and hardening properties of the cement by interference with prepolymerization.8
A study by Weisman et al. evaluating the mechanical strength of antibiotic free cement
and antibiotic impregnated cement using compression and elongation revealed a 32%
decrease in compressive and tensile strength when the antibiotic powder was added to the
liquid monomer compared to a 7% decrease in both when the antibiotic powder was
added to the powdered polymer.

13

The mechanical strength of the PMMA is of outmost

importance when used for arthroplasties, but not for AIPMMA bead production.

ANTIBIOTIC SELECTION
There are several important factors to consider when selecting an antibiotic for
incorporation in PMMA. The ideal antibiotic should be bactericidal, have broad-spectrum
activity, be effective at low concentrations, have a high water solubility, be
hypoallergenic, be biocompatible, have low tissue toxicity, be stable at temperatures up
to 100 C, have reduced effects on mechanical strength of the PMMA, and result in low
serum concentrations, but high concentrations in the target tissue. Most of the research
focuses on gentamicin-impregnated PMMA because of its commercial availability in
Europe.

8

Antibiotics such as colistimethate, polymixin B, tetracycline, and

chloramphenicol do not elute from the PMMA because of the inability to retain activity
after the heat produced during the exothermic reaction. 4, 14, 15, 16 Elution characteristics
from PMMA for multiple antimicrobials with good antibiotic release rates such as
5

aminoglycosides, -lactams, metronidazole, and macrolides have been described.

7, 17, 18

No antibacterial activity has been found in PMMA alone. 14, 15, 19, 20 Gentamicin blood
serum levels post-implantation are measurable, but not high enough that toxic side effects
should be a concern. Levels of 1 to 3ng/ml were measured immediately post-implantation
and dropped to less than 1ng/ml by six hours in one study. Low drug levels are
measurable in serum and urine for several months if the beads remain in the patient. In
human patients with normal renal function, the toxic daily dose is 3.4 mg/kg, and the
non-toxic dose is 2.6 mg/kg. Serum concentrations below 8 ng/ml appear to be safe in
preventing ototoxicity.

2

There have been no reports of ototoxicity associated with

gentamicin impregnated PMMA, and there is probably less risk of ototoxicity than with
long term systemic treatment with aminoglycosides. 2, 21

ANTIBIOTIC ELUTION
There are many factors that affect antibiotic elution from the beads such as type of
bone cement, antibiotic, concentration of the antibiotic, surface area of the bead, size of
the bead, shape of the bead, surrounding tissue and fluid flow around the bead.18 The
ideal cement bead would have an initial bactericidal antibiotic release followed by a
continuous bacteriostatic antibiotic release until the tissue has healed to a point where the
host’s immune system can kill any residual bacteria.14 The elution rate of antibiotics vary
depending on the type of cement used, and more complete antibiotic elutions have been
documented with Palacos® cement. 1, 19, 22 The difference in elution rates among different
cements is because of differences in surface pore size of the hardened cement. Palacos®
cement has a larger pore size compared to the others. 1, 14
6

ANTIBIOTIC ELUTION RATE
Results from previous studies revealed that the elution amounts and rates for
different antibiotics and antibiotic combinations vary. Antibiotic elution is bimodal, with
a fast elution rate within hours to days after implantation and a slow elution rate with
continued release during a period of weeks to months after implantation. Up to 5% of the
total amount of the antibiotic may elute during the first 24 hours.

8, 23

Antibiotic elution

from the bead surface may be responsible for the initial peak in the elution rate and
subsequent elution from the center matrix of the bead follows.1 Elution rate is directly
proportional to the surface area of the bead, the greater the surface area the greater the
elution. A small rough bead will elute better than a large smooth bead simply because
the small rough bead has a larger surface area per volume.8 A study evaluating the
relationship between bead geometry and elution of the antibiotic tobramycin revealed that
the best elution was from numerous, small and elliptically shaped beads.18 Antibiotic
tissue concentrations in wounds treated with local AIPMMA could reach as much as
twenty times the therapeutic levels obtained in serum after parenteral administration. The
high concentration reached locally may increase the spectrum of susceptible organisms in
spite of culture and sensitivity results reported. 9, 23, 24
The ratio of antibiotic to PMMA used to fabricate the bead also affects the amount
and rate of elution. Current recommendations based on biomechanical studies indicate a
limit of 10% of the weight for the antibiotic if the cement is used for implant fixation. 14
The addition of more than 4.5 g of an antibiotic to 40g of PMMA reduces compressive
strength below 70 Mpa (mega pascal), which is the minimum acceptable strength for
weight-bearing implants.

8

As the amount of antibiotic is increased, the surface pores
7

become larger, and the surface becomes rougher increasing the amount eluted. The ratio
for bead production is more forgiving since mechanical strength is not a concern, but
should not exceed an antibiotic to PMMA ratio of 1:5. If this ratio is exceeded the beads
will not harden.

14

Elution is also dependent on the tissue surrounding the beads and the

fluid flow. Vascular tissue has a higher absorption of the eluted antibiotic and a higher
elution rate than tissue with low vascularity. Granulation tissue and muscle being highly
vascular tissues have a higher elution rate than bone, which is a less vascular tissue.

BACTERIAL ADHERANCE
Neut et al. documented the retrieval of gentamicin-impregnated PMMA beads
after implantation for 5 years that were still eluting subinhibitory antibiotic
concentrations.25 This prolonged release of antibiotic at subinhibitory concentrations
could result in antibiotic resistant strains. Konstantinos et al. reported a 22% persistence
of bacterial growth on AIPMMA bead chains removed from patients with a history of
implantation because of an orthopedic infection.26 The mean duration of implantation in
these cases was 89 days. Once bacteria adhere to the implant, they could produce an
extracellular proteoglycan matrix or glycocalyx. The glycocalyx creates the perfect
environment for bacterial growth, inhibition of host immunity and antibiotic activity.26
An in vivo study evaluating the bacterial adherence to plain and tobramycin-laden beads
revealed bacterial adhesion on plain beads and no organisms on tobramycin impregnated
PMMA beads. Antibiotics eluting from the beads decrease exponentially over time,
eventually reaching subtherapeutic levels and allowing bacterial adherence. Bacterial
adherence post implantation may result in bacterial resistance. Therefore, it is
8

recommended to select an antibiotic based on culture and sensitivity results and remove
the beads after the antibiotic elution reaches subtherapeutic levels, which can vary from
weeks to months depending on the antibiotic.

27

Even though antibiotic bead removal is

the standard of care there are reports of prolonged implantation of Septopal® beads with
no evidence of complications. 23

CLINICAL APPLICATIONS
A randomized prospective study by Blaha et al. comparing the clinical efficacy of
gentamicin PMMA beads versus systemic therapy and a combination of PMMA beads
and systemic therapy for osteomyelitis did not prove any statistical superiority among
these treatments.21 The treatment cost of AIPMMA alone was significantly reduced when
compared with the systemic and combination treatments.21 A prospective, randomized,
controlled, closed study by Calhoun et al. comparing patients with infected nonunions
treated with intravenous antibiotics (Group I) or Septopal® beads and perioperative
broad-spectrum parenteral antibiotics (Group II) revealed a good success rate with both
treatments.28 Both groups were treated with surgical debridement and appropriate
reconstruction. The success rate for infection quiescence was 83.3% in Group I and
89.3% in Group II, and the success rate for uniting the nonunion was 83.3% in Group I
and 85.7% in Group II.

In this same study cases that needed retreatment with

debridement were considered failures. If the cases that required repeated debridement and
deemed failures in this study are taken into consideration, the Septopal® beads group had
a success rate of 94.2%. Success rates were better for the Septopal® beads group, and cost
for treatment was less when compared to the parenteral antibiotic group.28
9

Reported use of AIPMMA in animals is limited but has been reported for
prophylaxis in arthroplasties, limb-sparing procedures, treatment of septic arthritis in a
dog and treatment of cellulitis in an American black bear.29 A 4 year old, male, intact
English Bull Terrier with a history of septic arthritis and a positive culture for E. coli in
the right stifle after surgical correction of a cranial cruciate ligament rupture was treated
with intra-articular Septopal® beads for 20 days with excellent results.30 In a clinical
report by Dernell et al., 67% of dogs treated with tobramycin and vancomycin AIPMMA
for severe osteomyelitis post allograft replacement for osteosarcoma had resolution of the
condition within a median of 4 weeks post implantation.31 In the same study, 25% of
dogs had a recurrence with a median of 17 weeks post implantation. Even though the
success rate for resolution of osteomyelitis in this case series is low compared to previous
reports, no surgical debridement was performed because of the nature of the procedure
and the presence of internal fixation. A 6 year old bear with a history of abscessation and
skin necrosis in the right shoulder, forelimb and pectoral region was originally treated
with wound debridement and intermittent antibiotic administration without success. A
second surgical procedure with wound debridement, lavage, cefazolin impregnated
PMMA placement and primary closure was performed, and the wound was completely
healed 8 weeks after surgical repair.29
Local concentration and duration in which the concentration remains above the
break point susceptibility concentration (BPSC) post-implantation of the beads depends
on how fast the antibiotic elutes. Break point susceptibility concentration is the
concentration used to determine susceptibility or resistance of a particular bacterial
organism. Drug concentrations of 4 to 8 times the minimum inhibitory concentration
10

(MIC) for systemic therapy are recommended because the concentration of antibiotic
reaching the target tissue may be 20% to 25% of the plasma level.30 Treatment for an
existing infection should encompass use of effective antibiotic concentrations, preferably
based on culture and sensitivity results, for 3 to 4 weeks or longer depending on response
to treatment. The exact duration of time with an effective concentration needed for local
antibiotic treatment has not been documented to date.8 The activities of cefazolin and
meropenem are time dependent medications, and the amount of time that an antibiotic
concentration is above the MIC is of outmost importance. A concentration of one to five
times the MIC should be maintained for at least half of the dosing interval when time
dependent drugs are given systemically.31 The same guidelines are followed for local
treatment with time dependent antibiotics since the concentration needed for this purpose
is unknown, but it is assumed that the same rule applies.32
Local antimicrobial concentration and duration of elution after implantation of
AIPMMA beads varies depending on the antibiotic chosen.6, 33 An in vivo study in which
AIPMMA beads were implanted in a tibia of a dog revealed that antibiotic concentrations
in seroma fluid at the implantation site were above the MIC breakpoints for 3 to 28 days
for the antibiotics tested. The antibiotic concentrations were above the MIC breakpoints
through at least the following sampling days for the antibiotics listed: cefazolin, day 14;
ciprofloxacin, day 3; clindamycin, day 28; ticarcillin, day 9; tobramycin, day 21; and
vancomycin, day 3.1 Eventually the PMMA becomes encapsulated with fibrous tissue,
and antibiotic concentrations are limited to a 2 to 3mm area around the implant.1 Ramos
et al. reported that neither polymerization, gas sterilization, nor 2 month storage of

11

PMMA impregnated with gentamicin and metronidazole affected the bioactivity of the
antibiotic against E. coli and B. fragilis, respectively.9

OSTEOMYELITIS
Osteomyelitis is an infection of bone that can affect the bone medullary cavity,
cortex or periosteum. Bone infection is most commonly post-traumatic and caused by
bacteria, but viral and fungal osteomyelitis can also occur. Infections are acquired by
direct inoculation, extension from soft tissue infections or by hematogenous spread.34
Approximately 70% of open fractures and 40% of closed fractures have bacterial
contamination, but only a small percentage of these cases will develop infection. Factors
that may increase the risk of bone infection include impaired blood supply, foreign
material, devitalized bone, bone sequestration, unstable fracture fragments and severe
bacterial contamination.35 Even though several organisms can cause osteomyelitis, the
most common bacteria is Staphylococcus intermedius, which is responsible for 50% to
60% of bone infections in dogs. Other bacteria found in osteomyelitis are Streptococcus
spp., Actinomyces, Clostridium, Peptostreptococcus, Bacteriodes and Fusobacterium.
Anaerobic bacteria can be isolated in up to 70% of bone infections in dogs and cats if
proper sample collection methods are used. Caywood et al. found that the most common
source of bacteria leading to osteomyelitis was surgical technique accounting for 58% of
the cases.36 Clinical signs commonly associated with osteomyelitis include pyrexia,
erythema, swelling, local pain and lameness.

Treatment of osteomyelitis can be

challenging, costly and can have variable success rates sometimes ending in failure.10
Treatment includes surgical debridement of devitalized bone, lavage, fracture
12

stabilization, grafting of bone deficits and a prolonged course of systemic antibiotics for 4
to 6 weeks up to several months, as well as implantation of local antibiotic delivery
systems. Disadvantages of systemic antibiotic therapy include owner non-compliance,
systemic toxicity and antibiotic degradation or subtherapeutic antibiotic concentrations at
the infection site.17 One of the most important factors for successful treatment is to attain
high antibiotic concentrations at the infection site. However, this is not always possible
with systemic therapy.37 In addition, bacteria have the ability to protect themselves by
growing in colonies encased in an extracellular matrix of carbohydrate or glycocalyx that
increases bacterial adhesion and protection from phagocytes and antibodies.32,35
Organisms such as Staphylococcus epidermidis produce a slime that coats the implant
and results in an increase in bacterial resistance and forms a barrier against the host
immune response and antibiotics. Once a biofilm is present on the implant other
organisms can also adhere to the implant surface. This biofilm creates the perfect
environment for the organism, typically an organism of low virulence, to have a high
infective power with a low inoculum.39 The implants should be removed at the end of the
therapeutic period in order to prevent infections in the future.
Multidrug resistant (MDR) organisms have been an increasing cause of
nosocomial infections in human hospitals. Recently, there has been documentation of
increased MDR infections in veterinary facilities.40 As bacterial antibiotic resistance
continues to evolve, novel therapeutic strategies are needed to fight against MDR
bacteria.

13

ANTIBIOTIC STABILITY
Stability and elution of antibiotic after incorporation in the cement bead have been
reported for a gamut of antibiotics, but there are no reports, to date, evaluating the elution
characteristics of antibiotics in the carbapenem class. Meropenem is an intravenous betalactam antibiotic that belongs to the subgroup of the carbapenems. This antibiotic has the
widest spectrum of all carbapenems and is highly resistant to degradation by betalactamases, cephalosporinases and it is stable to dehydropeptidase-1. Meropenem’s
spectrum includes most aerobic and anaerobic gram positive and gram negative bacteria
with the strongest affinities for Escherichia coli, Pseudomonas aeruginosa, and
Staphylococcus aureus. Meropenem exhibits in vitro MIC90 of 4 mcg/ml or less for most
organisms including the organisms previously mentioned and anaerobes such as
Bacteroides spp., Clostridium spp., and Fusobacterium spp. Carbapenems are expensive
antibiotics that require intravenous administration and could affect renal and hepatic
function when administered parenterally.41 Even though there have been reports of
bacterial resistance to antibiotics in the carbapenem class in humans, to our knowledge
there are no documented reports of bacterial resistance in veterinary medicine.39
Staphylococci species that are resistant to methicillin or oxacillin should be considered
resistant to meropenem.41 Because of the wide spectrum of activity against gram-negative
and gram-positive organisms the use of carbapenems could lead to superinfections, and
therefore, are used as a last-line treatment in human medicine. Their use is limited in
veterinary medicine because of cost and to prevent bacterial resistance.
Cephalosporins are also incorporated into PMMA because this group of
antibiotics has a broad spectrum of activity. Cefazolin can withstand temperatures of
14

190°C before decomposition.30 The exothermic reaction of the polymerization of PMMA
does not exceed 120°C.42 Regular cycle steam and gas sterilization temperatures at our
hospital reach 135°C and 55°C, respectively. Neither of the temperatures used for the
sterilization process reaches high enough temperatures to result in antibiotic
decomposition. In an in vitro study evaluating the cefazolin elution from PMMA after
steam and gas sterilization no deleterious effects in the activity of the antibiotic were
observed using HPLC and disk agar diffusion methods.30 Cefazolin’s MIC for S. aureus
is 0.25 to 1.0 mcg/ml. This same study revealed the antibiotic may be available in local
tissues for a period of 7 to 10 days, but elution samples were only assayed intermittently
for 9 days.30 Traub and Leonhard evaluated the stability for sixty-one antibiotics at 56C
for 30 minutes and 121C for 15 minutes and found that both cefazolin and meropenem
were heat-labile antibiotics.44 Treatment of both antibiotics with 121C for 15 minutes
raised the MIC for common organisms more than 16-fold when compared with the no
treatment and the 56C treatment groups. Ethylene oxide treatment at 56C failed to raise
the MICs of any of the antibiotics tested by more than 2 fold with the exception of
tobramycin, which had a 4 fold increase when assayed against E. coli ATCC 25922.44
A freshly constituted solution of meropenem maintains satisfactory stability at the
95% level for up to 2 hours at a controlled room temperature of 15 to 25 C, or for up to
12 hours under refrigeration at 4 C. A study by Walker et al. found that stability of
meropenem was related to concentration and temperature. Walker et al. found that the
higher the concentration and the higher the temperature the faster the degradation of the
meropenem. A meropenem solution stored at -20 C retains 90% of the meropenem for at
least 11 days, and a meropenem solution stored at room temperature looses more
15

than10% within a 24 hour period. To date no studies have documented the degradation of
meropenem in a solution stored at -80 C. 40
To our knowledge no research has been published evaluating the in vitro elution
characteristics of meropenem impregnated PMMA beads. The objective of this study was
to determine the elution properties of meropenem and to compare the elutions of
meropenem impregnated PMMA beads without sterilization to those sterilized with steam
and ethylene oxide gas.

16

CHAPTER II
MATERIALS AND METHODS
A commercial metal cast polytetrafluoroethylene coated bead mold (University of
Vermont, Instrument & Model Facility, Burlington, VT, USA) was used. Each mold
produced one chain of 25 beads that were 6.4 mm in diameter. Surgical SimplexTM P
(Howmedica Inc, Rutherford, NJ, USA) radiopaque polymethylmethacrylate cement was
used to make the beads as previously described.1 Under a biocontainment hood, the
sterile polymethylmethacrylate powder was combined with commercial grade
meropenem powder (Merrem£: AstraZeneca Pharmaceutical LP, Wilmington, DE, USA)
at a ratio of 1:5 (4 g antibiotic:20 g PMMA) in a plastic bowl and thoroughly mixed with
a tongue depressor for 2 minutes.7,

45

The powder was then divided into four equal, 6

gram portions (1 gram antibiotic, 5 grams PMMA) utilizing a laboratory scale and placed
into specimen cups. Two and one half milliliters of the sterile polymethylmethacrylate
liquid was mixed with 6 grams of the powder mixture, then stirred for 30 seconds and
placed into two 10 cc syringes. A 22 gauge stainless steel cerclage wire was placed along
the slot inside the bead mold, and the mixture was injected into each hole of the bead
mold with gentle pressure. The beads were allowed to harden for 30 minutes, removed
from the bead mold and allowed to harden over 24 hours at room temperature (68-70qF).
This process was repeated four times to make five strands with a total of 125 beads of
which 120 were used. After 24 hours, the bead strands were cut into strands of 5 beads
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each. Negative control beads were made in the same fashion without the addition of
antimicrobial.
Forty beads were placed in an autoclave (PMMA-Auto) and sterilized for 15
minutes at 121°C. Forty beads underwent gas sterilization using ethylene oxide (PMMAEO) for 3 hours at 48.9oC. The final forty beads contained meropenem, but did not
undergo sterilization (PMMA-Cont) and served as a positive control group. Three groups
of forty PMMA beads without antimicrobial were treated in the same fashion and served
as negative controls.
Evaluation of the beads consisted of placing one strand of five beads in individual
test tubes (8 total test tubes per group) with 5 mls of sterile phosphate buffered saline
solution at pH 7.4. The beads were maintained at normal body temperature (37qC) and
constant horizontal agitation at 15 cycles per minute.45 The phosphate buffered saline
from experimental and control beads was sampled at all time periods by complete
evacuation of the 5ml eluent fluid. The eluent samples were placed in 7ml plastic vials
and stored at -80qC until assayed. Concentrations of the antibiotic in eluent samples from
the two sterilized groups and the control beads was determined using a microbiological
assay (MBA) at 1, 3, 6 and 12 hrs and at 1, 2, 3, 6, 9, 12, 15, 18, 22, 26, and 30 days.46
The disc diffusion method was performed as previously described in other studies.47 If
the amount of antimicrobial exceeded the highest standard curve, the eluted samples were
diluted with PBS before testing and adjusted accordingly.
Kocuria rhizophila, formerly classified as Micrococcus luteus ATCC 9341, was
cultivated on Antibiotic Medium No. 1 agar and stored at -80qC. It was thawed and
inoculated on a blood agar petri dish 24 hours before the bioassay test and was kept in an
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incubator at 37°C until used the next day. Kocuria rhizophila has been previously used to
assay a variety of antibiotics and fungicide residues.

48, 49, 50, 51

A BBLTM PromptTM

inoculation system (Beckton Dickinson Microbiology Systems, Sparks, MD, USA) was
used to prepare standardized suspensions adhering to the standards set by the National
Committee for Clinical Laboratory Standards. This inoculation system achieves the
desired inoculum density, equivalent to the 0.5 McFarland turbidity standard. All eluent
samples were thawed at room temperature and agitated before dilution or application to
the blank paper discs.
DIFCOTM antibiotic medium 11 (Becton, Dickinson and Company, Sparks, MD,
USA) was prepared following the manufacturer recommendations, autoclaved and poured
at 225 mls per Nunc plate (Thermo Scientific Nunc 245mm Square BioAssay Dish:
Fisher Scientific, Houston, Tx, USA) in a biocontainment hood, allowed to cool and
refrigerated until used. Each Nunc plate was inoculated with Kocuria rhizophila using the
Kirby-Bauer method and all the elution samples and quadruplets of the standard curves
(8, 16, 32, 64 and 128 mcg/ml) were randomized by drawing sample numbers from a
box. Each plate had duplicate internal standards of meropenem 16 mcg/ml that were used
to adjust for interplate variability in zone size. Concentrations reported below the lower
limit of the standard curve are because of division by a dilution factor and not
extrapolation beyond the lower limit. The plates were allowed to dry after inoculation for
10 minutes, 24 BBLTM 6mm diameter blank paper discs in duplicates were applied on the
surface of the agar plate equidistant from each other using a sterile technique, and 20l of
the designated sample was applied to each disk and allowed to dry for 15 to 20 minutes
before inverting the plate. The plates were incubated at 37°C for 24 hours. The zone
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diameters of the growth inhibition were measured using an electronic digital caliper 24
hours after inoculation and results were recorded for analysis. Areas of inhibition that
were faint or less than the diameter of the disc were recorded as no zone or not reliably
measured. The unknown released meropenem concentration for the in vitro samples was
determined by comparison of their respective zone size means with the standard curve. 52
The zone of inhibition is directly associated with drug response concentrations
(DRC). As the concentration of the drug increases the zone of inhibition should increase
if the organism is susceptible. This linear relationship between the diameters of the zone
of inhibition and the concentration of the drug allows use of the assay as a method for
quantification of a drug.
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CHAPTER III
RESULTS
The microbiological assay resulted in no zone of inhibition at all time periods for
the PMMA-Auto samples and the samples of PMMA without meropenem. Based on
Cartesian and semi-log plots, it was determined that the elution follows a first-order
process. The pharmacokinetic moment parameters are shown in Table 1. AUC0-
(mcg/ml hour) was 3,390.0 and 3,631.6 for PMMA-Cont and PMMA-EO, respectively.
MRT0- (hours) was 20.7 and 27.6 for PMMA-Cont and PMMA-EO, respectively. There
was no statistical difference in AUC0- (P< 0.318), however significance did occur for
MRT (P<0.005) when comparing PMMA-Cont and PMMA-EO with the later being
higher.
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Table 1.

Pharmacokinetic moment parameters for meropenem PMMA control and
sterilized by ethylene oxide gas

Parameter

PMMA-Cont

PMMA-EO

AUC0-
3390.0 + 593.15 3631.6 + 288.76
(mcg/ml hour)
*MRT0-
20.7 + 4.19

27.6 + 3.67

0.012 + 1.253

0.013 + 0.003

57.2

51.8

(hours)
Oz
(hour-1 )
t1/2
(hours)

Table 1. Average + one standard deviation of pharmacokinetic moment parameters for
meropenem PMMA controls (PMMA-Cont) and meropenem PMMA sterilized by
ethylene oxide (PMMA-EO). Oz is the first-order rate constant of the terminal elution
phase. Half-life (t1/2) was derived by dividing 0.693 by the terminal rate constant. The
SD of the rate constant reflects the variability of the half-life. * Denotes a value that has
statistically significant difference.
The cumulative drug elution released over 30 days for PMMA-Cont and PMMAEO totaled 2.6% ± 0.4% (±SD) and 2.9% ± 0.2% of the total amount incorporated in the
beads. The 24 hours elution for PMMA-Cont and PMMA-EO were 77.6% ± 4.6% and
66.6% ± 5.3%, respectively, of the total elution. The elution rapidly declined during the
remaining time period with a total elution for PMMA-Cont and PMMA-EO of 22.4% ±
4.6% and 33.4% ± 5.3%, respectively, of that total drug elution.
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The meropenem

concentration on the eluent remained above 4 mcg/ml for 15 days in the PMMA-Cont
group and until day 18 for PMMA-EO group.
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CHAPTER IV
STATISTICAL ANALYSIS
A pharmacokinetic analysis was performed as in previous studies by converting
the concentration of eluted drug versus time into rate of elution versus time.53 A modelindependent pharmacokinetic analysis using statistical moment theory was performed
using established equations based on area-under-the-curve calculations.53 In order to
calculate the area under the curve from time zero to infinity (AUC0-) and the mean
residence time from time zero to infinity (MRT0-) parameters, the terminal rate constant
(Oz) was determined by simple linear regression of all non-zero data points beyond 48
hours.
The analysis of Repeated Measures data was performed by using procedure
MIXED with the REPEATED statement on SAS PROC MIXED 9.2 computer software
(SAS Institute Inc, Cary, NC). The SUBJECT was TUBE (TREATMENT). The solution
in each tube was identified as subject, treatment (BIOASSAY) as between subject, TIME
as the categorical variable, and AR(1) (autoregressive of order 1) covariance structure to
specify the property of correlation of each tube being larger for nearby time point than
far-apart time point. Statistical analysis was performed using the concentration of drug
eluted versus time and the rate of elution versus time. A one-way ANOVA was used for
comparison of the pharmacokinetic parameters. The level of significance was set at P<
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0.05. All samples were performed in eight replicates to allow meaningful interpretation of
results.
Statistical analysis of least squares means for the mean concentrations of
meropenem showed a statistically significant difference between PMMA-Cont and
PMMA-EO at 6, 12, and 24 hours and at 2, 3, 6, and 9 days. No statistically significant
difference was found at 1 and 3 hours and 12, 15, 18 and 22 days. Statistical analysis of
least squares means for the buffer concentrations showed a statistically significant
difference between PMMA-Cont and PMMA-EO at 3 hours and the baseline. No
statistically significant difference was found at 9, 12, 15, 18, 21, and 24 hours and at 5,
10, 15, 20 and 25 days.
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CHAPTER V
DISCUSSION
This in vitro study provides information about the potential clinical use of local
meropenem therapy and the feasibility of bead prefabrication and sterilization for future
use. Results of our study indicate that meropenem elutes effectively from PMMA, and
the meropenem concentration on the eluent remained above 4 mcg/ml for 15 days in the
PMMA-Cont group and until day 18 in the PMMA-EO group. No growth inhibition zone
was observed on any of the samples after steam sterilization, indicating a complete loss
of antibacterial activity. Because of the loss of antibacterial activity for PMMA-Auto
samples no statistical comparison to the other treatments was possible. A mean
cumulative drug elution for PMMA-Cont and PMMA-EO during 30 days totaled 3,210
mcg and 3,397 mcg, respectively (Fig. 1). This represents 2.6% ± 0.4% (±SD) of the total
initial amount incorporated in the beads for PMMA-Cont and 2.9% ± 0.2% for PMMAEO (Fig. 2 and 3). This finding is in accordance with previously reported antibiotic
elution percentages from PMMA ranging from 2.3% to 11% for penicillins,
cephaloridine, clindamycin, sodium fusidate and gentamicin.54 Our study also supports
the previous finding that PMMA alone does not have any antibacterial activity under the
conditions studied. 10, 14, 19, 54
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Figure 1

Meropenem mean concentration- Ethylene Oxide and Steam Sterilization

PMMA-Cont- PMMA-EO- The graph shows that the mean concentration for
meropenem remained above 4mcg/ml for 15 days (360 hours) in the PMMA-Cont
treatment group and until day 18 (432 hours) for PMMA-EO.

Figure 2

Meropenem percent for the 1st phase elution

PMMA-Cont- PMMA-EO- The graph shows the rapid decline of the total percentage
of antibiotic eluting from the PMMA beads during the 1st elution phase (first 24 hours).
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Figure 3

Meropenem percent for the 2nd phase elution

PMMA-Cont- PMMA-EO- The graph shows the declining percentage of antibiotic
eluting from the PMMA beads during the 2nd elution phase in the group treated with
ethylene oxide and the group with no sterilization treatment.
Meropenem’s elution pattern is biphasic, which is similar to patterns reported for
other antibiotics.10 This biphasic elution is suspected to be the result of initial antibiotic
elution from the surface of the bead and a sustained release during the second phase of
elution from the bead matrix.54 Approximately 40% of the cumulative antibiotic elution
occurred during the first hour.
There was no statistical difference in area under the curve comparisons of
PMMA-EO and PMMA-Cont indicating that the total release of meropenem was
equivalent. This finding confirms that gas sterilization of meropenem impregnated
PMMA beads with ethylene oxide did not adversely affect antibiotic activity nor elution.
Previous studies describe similar results with other antibiotics, and gas sterilized
AIPMMA beads have been used successfully in the treatment of horses with localized
infections. 55, 56, 57 Ramos et al. reported that neither polymerization, gas sterilization, nor
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2 month storage of AIPMMA with varied antibiotics affected the bioactivity of the
antibiotic against a common pathogen.10 In our study the MRT did differ significantly,
suggesting that ethylene oxide sterilization resulted in slightly longer elution time, though
there would likely be no clinical significance in this increase (7 hours).
The minimum inhibitory concentration (MIC90) for the most commonly
encountered pathogens in cases of osteomyelitis and soft tissue infections sensitive to
meropenem is 4 mcg/ml.58 The activity of meropenem is time dependent, and the amount
of time that an antibiotic concentration is above the MIC is important. In the study
reported here, the meropenem concentration in the eluent remained above 4mcg/ml for 15
days in the PMMA-Cont group and for 18 days in the PMMA-EO group. When
addressing an existing infection, it is recommended that treatment involve the use of
effective antibiotic concentrations for 3 to 4 weeks or longer depending on response to
treatment. 59, 60 It is also recommended that a concentration of one to five times the MIC
should be maintained for at least half of the dosing interval when time dependent drugs
are given systemically.32 However, the concentration that should be maintained over time
when a time-dependent antibiotic is used for local treatment is unknown. This should be
considered when using meropenem impregnated beads for treatment of existing
infections.
Antibiotic elution rate varies depending on the type of cement used.14,

54

SimplexTM P radiopaque polymethylmethacrylate cement was selected for this study
because it is the most commonly used cement in the United States.7 However, Palacos®
(Heraeus, Kulzer GmbH, Hanau, Germany) bone cement has been found to release most
antibiotics in larger amounts and for longer periods of time than other bone cements
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because of a larger surface pore size.

16, 19, 61

Also, a previous in vitro study evaluating

vancomycin elution from PMMA and biodegradable beads reported extended antibiotic
elution times when biodegradable beads were used.61
Implant size also affects antibiotic elution, with smaller beads having a greater
surface area and as a result a better elution than larger beads.54 The PMMA beads used in
this study were 6.4 mm in diameter as described in previous studies.6,

7

Though

biomechanical studies on antibiotic impregnated PMMA indicate that no more than 10
percent of the total weight should be antibiotic if the cement is used for implant fixation,
the percentage can be much higher for bead production. The limit of antibiotic to PMMA
ratio recommended for bead production is 1:5. If the amount of antibiotic surpasses this
ratio the PMMA will not harden into beads.54
The volume of PBS used and the elution rates affect the antibiotic concentration
in the eluent. The PBS volume chosen for this study was the same as used in previous
studies.45 The use of serum instead of PBS has not been found to affect elution rates. 45
Meropenem is an intravenous beta-lactam antibiotic that belongs to the subgroup
of the carbapenems. It is highly resistant to degradation by beta-lactamases,
cephalosporinases, and it is stable to dehydropeptidase-1. Meropenem’s spectrum
includes most gram positive and gram negative bacteria with the strongest affinities for
Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Meropenem
exhibits in vitro MIC90 of 4 mcg/ml or less for most organisms including the organisms
previously mentioned and anaerobes such as Bacteroides spp., Clostridium spp., and
Fusobacterium spp. Though there have been reports of bacterial resistance to antibiotics
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in the carbapenem class in humans, to our knowledge there are no documented reports of
bacterial resistance in veterinary medicine.62
Beta-lactam antibiotics have been classified as heat-labile antibiotics.

The

exothermic reaction during polymerization of PMMA can reach temperatures of 100C
and may result in degradation and inactivation of certain antibiotics. 4, 14, 15, 16, 44, 63, 64 In a
study of meropenem, the MIC for various organisms increased about 16-fold after
autoclaving at 121 C for 15 minutes, presumably from alteration of a key portion of the
molecule necessary for antimicrobial activity. Autoclave treatment increased the MIC for
all the organisms tested, but did not result in complete destruction of the antimicrobial
activity. No change in MIC was observed after heat treatment with 56C for 30 minutes
in a water bath.44 Our study did not support the use of meropenem impregnated PMMA
beads after autoclave sterilization since no growth inhibition zone was observed on any
of the PMMA-Auto samples. The exothermic reaction combined with the exposure to
121 C for 15 minutes during autoclaving may have rendered the meropenem
incorporated into the cement bioactively inert. Whereas the PMMA-Cont beads with no
sterilization treatment did have a growth inhibition zone and the results were not
significantly difference than samples sterilized with ethylene oxide gas.
Imipenem, another antibiotic in the carbapenem subgroup, has been incorporated
in PMMA pellets approximately 12mm in length and 7 mm in diameter resulting in shortterm, less than adequate elutions, but antibiotic elution was only evaluated for the first 72
hours.63 In the same study a 3:1 mix of polymer and monomer was used for preparation
of the PMMA pellets to produce a lower peak temperature during polymerization of the
cement, resulting in a 65 C compared with a 75C in a 2:1 mixture. Imipenem’s MIC for
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common pathogens increased more than 256 fold when autoclaved at 121 C for 15
minutes in a previous study evaluating heat stability.44
A potential limitation of this study is that the eluted samples were stored at -80C
for up to 3 months prior to testing. Meropenem serum concentrations are reported to be
stable during -20C freezing for greater than 20 days, though no published reports
describe stability of higher concentrations for longer periods of time.46 It is possible that
the antibiotic degraded during storage. If this occurred, meropenem activity may be
longer than identified in this study. Additional studies would be needed to determine
degradation rate for meropenem during storage at -80C.
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CHAPTER VI
CONCLUSION
Our study found that meropenem incorporated in the PMMA beads elutes
effectively and gradually decreases during the second elution phase, but remains above
concentration of 4mcg/ml for 15 days in the PMMA-Cont group and until day 18 for
PMMA-EO group.

Meropenem impregnated PMMA beads can be sterilized using

ethylene oxide without adversely affecting antibiotic activity, though the shelf-life of
prefabricated meropenem beads for “off the shelf” use needs further investigation.
Several factors affecting the antibiotic elution could be used in order to increase
meropenem elution such as bead size, decrease in the amount of monomer, increase the
amount of antibiotic incorporated in the cement, use of a more oblong bead shape to
increase bead surface area and use of biodegradable materials such as hydroxyapatite,
calcium

sulfate

hemihydrate

and

polylactide-polyglycolide.

The

effects

and

pharmacokinetics of meropenem impregnated PMMA bead implantation should be
evaluated

in

vivo

to

determine
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clinical

applications.
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